1Q Earnings Preview: What To Expect From US, EU Big Hitters

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

Bernstein analysts expect Eli Lilly & Co. and several other big pharma companies that report earnings in US dollars to get a boost from the continued strengthening of the US dollar, creating a foreign exchange headwind after recent quarters when exchange rates hurt pharma revenues. Bernstein's Tim Anderson expects the company to report $0.88 in earnings per share (EPS) and $5bn in first quarter revenue, including a boost from recent sales growth for diabetes starJardiance (empagliflozin), which Lilly recently said it would test as a treatment for heart failure. Consensus estimates are for $4.8bn in revenue and EPS of $0.85. Investors will look for early sales figures from new products, including the recently approved Taltz (ixekizumab) for psoriasis (Also see "FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx " - Scrip, 23 March, 2016.).

As for future growth, expect analysts to derive new insights from Lilly executives about the company's most anticipated clinical data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.